8-K: Microbot Medical Achieves ISO 13485 Certification, Paving Way for European and US Regulatory Approvals

Microbot Medical has received ISO 13485:2016 certification for its quality management system, a key step towards obtaining regulatory approvals in Europe and streamlining compliance with revised FDA regulations.

Summary

• Microbot Medical has been awarded ISO 13485:2016 certification for its quality management system.
• This certification is a critical requirement for obtaining CE mark approval, which is necessary for selling medical devices in the European Union.
• The company believes this certification will also help streamline its transition into the revised FDA quality system management regulation (QMSR), which incorporates the ISO 13485 standard.
• The ISO 13485 standard is specifically designed for the medical industry and requires a rigorous approach to risk assessment and management of all processes related to the development and manufacturing of regulated medical products.
• The company's compliance with ISO 13485 demonstrates its commitment to consistently reviewing and validating its product development and manufacturing processes.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to the achievement of a key regulatory milestone (ISO 13485 certification) which is essential for future commercialization. The company is progressing as expected.

Positives

• The ISO 13485 certification is a significant milestone for Microbot Medical, demonstrating a robust quality management system.
• This certification is a prerequisite for obtaining CE mark approval, allowing the company to sell its products in the European Union.
• The certification is expected to streamline the company's transition to the revised FDA quality system management regulation.
• The company's achievement of this certification indicates that it is building the necessary capabilities and infrastructure for commercialization.

Risks

• The document mentions that forward-looking statements involve risks and uncertainties, including market conditions, risks inherent in the development and commercialization of the LIBERTY Endovascular Robotic Surgical System, and the outcome of studies.
• There are risks associated with regulatory pathways and approvals, including the success of the company's pivotal study in humans.
• The company faces risks related to recruiting physicians and clinicians for regulatory studies, which could delay such studies.
• Disruptions from geopolitical events, such as hostilities between Israel and the Palestinians, and the lingering effects of the COVID-19 pandemic, could also impact the company.
• The company's ability to obtain future capital and maintain intellectual property rights are also potential risks.

Future Outlook

The company is progressing towards commercialization of its LIBERTY Endovascular Robotic Surgical System and anticipates that the ISO 13485 certification will support future regulatory submissions and approvals.

Management Comments

• Noa Ofer, PhD, Sr. Director of Quality Assurance and Regulatory Affairs, stated that the certification is a testament that they are building the right capabilities and infrastructure as they progress toward commercialization.
• The management believes that the LIBERTY Endovascular Robotic Surgical System has the potential to democratize endovascular interventional procedures.

Industry Context

The achievement of ISO 13485 certification is a common and necessary step for medical device companies seeking to commercialize their products in regulated markets like the European Union and the United States. This certification is particularly relevant given the recent revisions to the FDA's QMSR, which now incorporates the ISO 13485 standard.

Comparison to Industry Standards

• ISO 13485 certification is a globally recognized standard for quality management systems in the medical device industry.
• Companies like Medtronic, Johnson & Johnson, and Stryker also maintain ISO 13485 certification as part of their regulatory compliance efforts.
• The certification is a benchmark for demonstrating a company's commitment to quality and safety in the development and manufacturing of medical devices.
• The CE mark, which is enabled by ISO 13485, is a requirement for selling medical devices in the European Union, similar to FDA approval in the United States.

Stakeholder Impact

• The ISO 13485 certification is a positive development for shareholders, as it increases the likelihood of future regulatory approvals and commercial success.
• The certification also benefits employees by demonstrating the company's commitment to quality and compliance.
• The certification is a step towards bringing the LIBERTY Endovascular Robotic Surgical System to market, which could ultimately benefit patients by improving clinical outcomes and increasing accessibility to endovascular procedures.

Next Steps

• The company will continue to work towards obtaining CE mark approval for sales in the European Union.
• Microbot Medical will also focus on transitioning to the revised FDA quality system management regulation (QMSR).

Key Dates

Keywords

ISO 13485, Quality Management System, CE Mark, FDA, Medical Device, Regulatory Approval, LIBERTY Endovascular Robotic Surgical System, Commercialization, QMSR